Tag: FDA

Posted on

Ping: Partisipasyon ng Pribadong Sektor, LGU sa Vaccination Program Palakasin

Ituring na katuwang ang pribadong sektor at mga lokal na pamahalaan sa programang pagbabakuna ng pamahalaan laban sa COVID-19, sa halip na tratuhin sila bilang kakompetensiya.

Kasabay nito, nanawagan si Senador Panfilo Lacson na mas palakasin ang partisipasyon ng pribadong sektor at mga lokal na pamahalaan sa naturang programa sa pamamagitan ng pagluluwag sa mga ito na makaangkat at maisagawa ang proseso ng pagbabakuna.

Ang kailangan lamang umano ay matiyak ang regular na koordinasyon ng mga ito sa mga mangangasiwa sa programa, ang Department of Health (DOH) at National Task Force Against COVID-19.

“One common mistake that every administration commits is treating the private sector as competitors through over-regulation instead of partners especially during the time of crisis such as this pandemic that we are confronting now,” banggit ni Lacson.

“Let’s face the reality that the private sector does not go through the same bureaucratic delays that their counterpart in the public sector suffers from,” obserbasyon ng mambabatas.

Related: Lacson Pushes Greater Private Sector, LGU Participation in Vaccination Program
Continue reading “Ping: Partisipasyon ng Pribadong Sektor, LGU sa Vaccination Program Palakasin”

Posted on

Lacson Pushes Greater Private Sector, LGU Participation in Vaccination Program

The private sector and local government units (LGUs) should be treated as partners and not competitors in the national government’s COVID-19 vaccination program by being allowed to actively and even proactively procure and administer vaccines, Sen. Panfilo M. Lacson stressed Monday.

Lacson said this is as long as they are in close coordination and under the supervision of the Department of Health and National Task Force Against COVID-19.

“One common mistake that every administration commits is treating the private sector as competitors through over-regulation instead of partners especially during the time of crisis such as this pandemic that we are confronting now,” he said.

“Let’s face the reality that the private sector does not go through the same bureaucratic delays that their counterpart in the public sector suffers from,” he added.

Related: Ping: Partisipasyon ng Pribadong Sektor, LGU sa Vaccination Program Palakasin
Continue reading “Lacson Pushes Greater Private Sector, LGU Participation in Vaccination Program”

Posted on

Ping: Gobyerno May “Chosen One” Bakuna Na

Malinaw na malinaw ang mga senyales na may “chosen one” na bakuna laban sa COVID-19 ang gobyerno, sa kabila ng kawalan pa ng Emergency Use Authorization (EUA) sa kahit na anong kumpanyang gumagawa nito.

Ayon kay Senador Panfilo Lacson, ang binabanggit ng gobyerno na Sinovac lamang ang puwedeng magamit hanggang sa Hunyo ay nagpapatunay ng pagkakaroon na ng “chosen one” na bakuna.

“Can somebody explain why preference is given to the second most expensive vaccine, has lower efficacy, a record of suspended clinical trials and has not even applied for Emergency Use Authorization (EUA) over other vaccines that cost much less, more efficacious and are about to be granted their EUAs?” banggit ni Lacson sa Twitter.

Mas makatuwiran umano para sa mga Pinoy kung ang pagtrato ng gobyerno sa Sinovac ay gagawin din sa mga bakuna ng ibang bansa na di-hamak na mas epektibo at mas mababa ang presyo, ayon sa mambabatas.

“That said, the national government should expedite the procurement of all qualified and available vaccines. To borrow Secretary Harry Roque Jr.’s words, it should not be choosy in buying vaccines,” diin ni Lacson.

Related: Why Choosy? Lacson Scores Sinovac’s 5-Month Headway
Continue reading “Ping: Gobyerno May “Chosen One” Bakuna Na”

Posted on

Why Choosy? Lacson Scores Sinovac’s 5-Month Headway

After telling ordinary Filipinos not to be choosy in getting their COVID vaccines, the government should apply the same line in expediting the procurement of all qualified and available vaccines, Sen. Panfilo M. Lacson said Wednesday.

Lacson noted the availability of only Sinovac until June, as well as the replies of officials at Monday’s Senate hearing, indicate China-based Sinovac is the “chosen one.”

“Can somebody explain why preference is given to the second most expensive vaccine, has lower efficacy, a record of suspended clinical trials and has not even applied for Emergency Use Authorization (EUA) over other vaccines that cost much less, more efficacious and are about to be granted their EUAs?” Lacson asked on Twitter.

“That said, the national government should expedite the procurement of all qualified and available vaccines. To borrow Secretary Harry Roque Jr.’s words, it should not be choosy in buying vaccines,” he added.

Related: Ping: Gobyerno May “Chosen One” Bakuna Na
Continue reading “Why Choosy? Lacson Scores Sinovac’s 5-Month Headway”

Posted on

On the DOH’s ‘Adjustments’ in Dealing with the COVID-19 Threat

At last, the Department of Health leadership is making some adjustments to address the COVID-19 threat, but only now after so much time has been wasted.

For one, through the private sector’s initiative in coordination with the Inter-Agency Task Force on Emerging Infectious Diseases and other government agencies, massive rapid testing will start tomorrow, April 14, if it is not being done already.

Secondly, contact tracing, hopefully, will now be more efficient with the latest guideline issued by IATF for mandatory disclosure of COVID-19 infected persons for more efficient self-quarantine.

Thirdly, after a long and unnecessary delay, the FDA approved the use of test kits – including at least 10 rapid antibody test kits and 23 PCR-based test kits as of April 8. The delay was amid the willingness of private donors to spend big money to help accelerate mass testing through the use of rapid antibody test kits, and even after we asked the FDA about the usefulness of such rapid test kits as early as our March 24 caucus prior to our 18-hour plenary debates to pass Republic Act 11469 (Bayanihan to Heal As One Act) on the same day, with some Cabinet members in attendance.

What I can’t understand for the life of me is why the DOH keeps issuing circulars that seem to circumvent Sec 4(j) of the Bayanihan Act that provides for some leeway for donated test kits that otherwise have already been in use in other jurisdictions, by mandating the turnover of all donations to DOH but would not allow its use. This is compounded by a requirement for accreditation that includes, among others, an application by the manufacturer or distributor of such health products. Since these are donations and therefore not for business purposes, how in the world will these donors look for local distributors, or look for the manufacturer to file for an application? Sec 4(j) specifically states that all donated health products need only a certification from the regulatory agency/ies of the country that allows the use of such health products for FDA to approve the same.

On the other hand, there is no saying that Secretary Carlito Galvez Jr. is not doing a good job as chief implementer of the government’s national response against COVID-19, by playing catch-up for the inadequacies of some people.

*****